Malabsorption Syndrome Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Malabsorption Syndrome Market Trends and Insights

Rising Prevalence of Gastrointestinal and Pancreatic Disorders

India had become the leading country for new inflammatory bowel disease incidence by 2025, which changes the geographic focus of the malabsorption syndrome market. The 2024 European guidelines extended pancreatic enzyme replacement therapy indications beyond chronic pancreatitis to patients after bariatric surgery, type 2 diabetes, and esophageal surgery. This combination of a growing Asian inflammatory bowel disease population and wider pancreatic insufficiency eligibility increases the number of patients who may need long-term treatment. Companies with existing biologic or enzyme replacement products can serve these populations without developing separate treatment platforms.

Broader Screening and Diagnostic Access

The 2025 European Society for the Study of Coeliac Disease guidelines permitted a conditional biopsy-free pathway for selected adults younger than 45 years ^{[1].Source: “European Guidelines for the Diagnosis and Treatment of Pancreatic Exocrine Insufficiency,” United European Gastroenterology Journal, uegjournal.org.} The pathway requires IgA anti-TG2 levels of at least 10 times the upper limit of normal and confirmation through a second serology test. France’s Haute Autorité de Santé stated in 2026 that only 10% to 20% of its estimated 670,000 affected patients had a confirmed diagnosis. Germany reported a diagnosis delay of 5 to 7 years and an undiagnosed rate of up to 80%, while Italy introduced a public pediatric screening program in 2025. These differences in access create uneven demand across Europe. Serology-first pathways can reduce procedural barriers and may bring more patients into dietary, nutrition, and treatment programs.

Expansion of Clinical Nutrition and Enzyme Replacement

The 2024 European guidance described pancreatic enzyme replacement therapy as a central part of managing exocrine pancreatic insufficiency. It also required dietary counseling and nutritional monitoring alongside enzyme treatment. This approach broadens prescribing beyond traditional gastroenterology care because nutrition support is needed throughout the patient pathway. Entera Bio reported in 2025 that teduglutide generated USD 800 million in annual sales despite daily subcutaneous administration requirements. The reported sales level indicates established payer acceptance for high-value short bowel syndrome therapies. Fresenius stated that 1-quarter of hospitalized patients in European studies faced substantial malnutrition risk, creating a broad base for enteral and parenteral nutrition demand. The malabsorption syndrome market, therefore, benefits from care needs that extend beyond patients with a confirmed diagnosis.

Aging and Pediatric High-Risk Populations

The global population aged 60 years and older is projected to reach 2 billion by 2050, compared with 1 billion in 2020. Older populations have higher exposure to pancreatic insufficiency, inflammatory bowel disease-related malnutrition, and bile acid malabsorption. Japan and Germany have rapidly aging populations, supporting demand for prolonged nutrition support and pharmacological care. A 2025 study reported that parenteral nutrition requirements fell by as much as 54.60% in adults with childhood-onset short bowel syndrome and by as much as 31.90% in pediatric patients receiving a GLP-2 analog. Early intervention may allow pediatric survivors to enter adulthood with continuing needs for monitoring, enzyme replacement, or periodic nutrition support. Providers that combine biologics with clinical nutrition services can maintain contact across this long care period.

High Therapy and Diagnostic Costs With Uneven Reimbursement

The average cost of preparing a home parenteral nutrition bag increased 75.40% in the United States between 2016 and 2024. Reimbursement declined from 2022 to 2024, while 17 of 24 parenteral nutrition compounding ingredients appeared on shortage lists at the same time. Home parenteral nutrition pharmacy providers declined by an average of 15.60% annually, and Medicare beneficiaries using home enteral nutrition declined 27% under the Competitive Bidding Program. March 2025 coverage guidance added documentation requirements for parenteral nutrition reimbursement. These conditions increase the administrative and financial burden for homecare suppliers. Hospital-based nutrition providers face fewer reimbursement barriers than independent home infusion providers.

Underdiagnosis and Nonstandardized Diagnostic Pathways

Germany’s 2026 report showed that patients waited an average of 5 to 7 years for a celiac disease diagnosis, and up to 80% of cases remained unidentified. Italy’s pediatric screening program demonstrates how public policy can produce a different level of case finding within the same region. The American College of Gastroenterology continues to support biopsy confirmation for most adults, whereas the 2025 European guidance allows selected adults to receive a serology-only diagnosis. A Spanish study published in 2025 also found a material gap between serologically detected and clinically coded celiac disease. Diagnostic suppliers must support different validation and clinical evidence requirements across these systems. This variation slows the conversion of disease burden into diagnosed treatment demand.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease: Celiac Disease Holds the Largest Share, While Short Bowel Syndrome Gains Momentum

Celiac disease accounted for 34.70% of the malabsorption syndrome market share in 2025. Its position reflects a broad patient base across Europe and North America, where prevalence is estimated at 1% to 2% of the global population^{[2]Source: “EASE-5, Efficacy and Safety Evaluation of Glepaglutide in Short Bowel Syndrome,” ClinicalTrials.gov, clinicaltrials.gov.}. Inflammatory bowel disease remains an important revenue contributor because biologic pipelines address a growing pool of chronic patients. Pancreatic and enzyme deficiency disorders gained relevance after European guidelines widened exocrine pancreatic insufficiency indications. The other categories include lactase deficiency, small intestinal bacterial overgrowth, and tropical sprue, which contribute to narrower volumes. The disease mix requires suppliers to serve conditions with different diagnostic routes and treatment durations.

Short bowel syndrome and intestinal failure are projected to record an 8.90% CAGR through 2031, the highest growth rate among disease categories. The malabsorption syndrome market size for this category is supported by GLP-2 analog development and stronger survival outcomes after pediatric surgery. Teduglutide generated USD 800 million in annual sales despite daily injections, showing willingness to fund therapies for patients with severe intestinal failure. Zealand Pharma initiated the EASE-5 Phase 3 study of 10.00mg twice-weekly subcutaneous glepaglutide in February 2026. The study enrolled 90.00 patients in the United States and Europe. Entera Bio also presented pharmacokinetic data for an oral GLP-2 tablet in 2025, placing convenience and adherence alongside clinical efficacy in product competition.

By Offering: Treatment Remains the Main Revenue Base, While Diagnosis Expands

Treatment held 61.80% of the malabsorption syndrome market share in 2025. This includes dietary management, medical nutrition, pancreatic enzyme replacement therapy, and biologic medicines. Anti-inflammatory biologics have the highest per-patient revenue potential in inflammatory bowel disease. Annual biologic spending in the United States commonly exceeds USD 20,000 for these patients. Enzyme replacement and nutritional supplements address the different needs of patients with pancreatic insufficiency and short bowel syndrome. The broad treatment range supports a large installed base of recurring care.

Diagnosis is forecast to grow at an 8.10% CAGR through 2031. The 2025 European conditional no-biopsy pathway raises the importance of validated IgA anti-TG2 immunoassay platforms. Fresenius Kabi launched 3.00 enteral nutrition products in 2025 and received European approval for PediSmof, a three-chamber pediatric parenteral nutrition bag. Its 2025 vedolizumab biosimilar licensing agreement also extended its work from nutrition into gastrointestinal immunology. Endoscopy and biopsy may face lower volumes in parts of Europe where noninvasive protocols gain acceptance. North American providers continue to use biopsy for most adult patients, preserving demand for both procedural and serological diagnostic approaches.

By Route of Administration: Oral Products Lead, While Subcutaneous Therapies Grow Faster

Oral administration accounted for 72.40% of the malabsorption syndrome market share in 2025. The category includes pancreatic enzyme capsules, oral nutrition supplements, and gluten-free medical nutrition products. These products support the majority of outpatient malabsorption cases because they fit routine, long-term use. Parenteral and enteral routes serve patients with severe digestive impairment. They produce recurring demand for tube-feeding formulas and multichamber parenteral nutrition bags. Route selection is determined by disease severity, gastrointestinal function, and the ability to maintain nutrition outside the hospital.

Subcutaneous administration is forecast to grow at a 9.40% CAGR through 2031. AbbVie submitted a U.S. application in April 2026 and a European application in August 2026 for subcutaneous SKYRIZI induction in Crohn’s disease. The Phase 3 AFFIRM data included 65.00% of enrolled patients who had failed prior advanced therapies. Glepaglutide is also being studied with a twice-weekly subcutaneous autoinjector, supporting the route’s role in next-generation GLP-2 treatment. Fresenius Kabi’s PediSmof three-chamber bag provides a standardized parenteral option for pediatric patients. The product reduces manual compounding requirements and supports more consistent dosing from premature neonates through adolescents.

By Distribution Channel: Hospital Pharmacies Lead, While Online Pharmacies Build Scale

Hospital pharmacies held 44.20% of the malabsorption syndrome market share in 2025. Their position reflects the role of infusion therapies, complex parenteral nutrition compounding, and inpatient diagnostics. Retail pharmacies supply pancreatic enzyme preparations and oral nutrition products to ambulatory patients. Direct institutional sales support large health systems through longer supply agreements. Fresenius Kabi signed a 2025 full-line agreement with a major U.S. institution that included 7,000.00 Ivenix pumps and parenteral nutrition products. These arrangements reinforce hospital purchasing relationships for complex nutritional care.

Online pharmacies are forecast to grow at a 10.20% CAGR through 2031. Digital prescription fulfillment, telehealth links, and cold-chain delivery can reduce refill barriers for patients with chronic gastrointestinal conditions. The Preserving Patient Access to Home Infusion Act was referred to the U.S. Senate Finance Committee in March 2025. The proposed legislation seeks to expand Medicare reimbursement for professional pharmacy services on non-nursing infusion days. If adopted, the policy could improve the economics of direct-to-home dispensing. Online channel growth depends on reimbursement, delivery reliability, and continued pharmacist support for patients using complex nutrition therapies.

By End User: Hospitals Hold the Largest Base, While Homecare Grows

Hospitals accounted for 46.50% of the malabsorption syndrome market share in 2025. They manage inflammatory bowel disease flares requiring intravenous biologics, acute malabsorption episodes, and initiation of parenteral nutrition after surgery. Specialty clinics and nutrition centers support longer-term inflammatory bowel disease monitoring, celiac follow-up, and outpatient pancreatic enzyme management. Diagnostic and research centers contribute through endoscopy services and specialized serological testing. Hospitals also remain central when patients need complex monitoring or nutrition stabilization. This care role sustains their position as the largest end-user setting.

Homecare settings are forecast to grow at an 8.70% CAGR through 2031. The malabsorption syndrome market size in homecare is supported by care-site migration policies, aging populations, and infusion technologies that enable parenteral nutrition outside hospitals. Baxter UK announced its Patient Ordering Platform in June 2026 for home parenteral nutrition patients. The platform is intended to support online supply management while retaining telephone assistance. Home delivery can improve adherence to scheduled supplies when clinical oversight is maintained. Reimbursement pressure remains the key limitation because home infusion providers face rising compounding costs and reduced payment support. The balance between cost coverage and home-based care needs will determine how quickly this setting grows.

Geography Analysis

North America held 40.80% of the malabsorption syndrome market share in 2025. Medicare’s parenteral nutrition coverage framework and a concentrated specialist pharmacy network support the region’s position. The United States had the highest total inflammatory bowel disease patient count of any country in 2025. Fresenius Kabi’s 2025 agreement for 7,000 Ivenix pumps and parenteral nutrition products shows the scale of institutional procurement in the region. Canada had the highest age-standardized inflammatory bowel disease prevalence rate, supporting high treatment intensity. North American growth is constrained by the 75.40% rise in home parenteral nutrition preparation costs from 2016 to 2024 and reimbursement declines since 2022.^{[3]Source: “From West to East, Dissecting the Global Shift in Inflammatory Bowel Disease Burden,” BMC Public Health, link.springer.com.}

Europe is the second-largest regional group in the malabsorption syndrome market. Italy introduced a legally mandated celiac screening program for children in 2025, while Germany continued to report diagnosis delays of 5 to 7 years and underdiagnosis of up to 80.00%. France’s updated 2026 recommendations recognized that only 10% to 20% of an estimated 670,000 affected people had confirmed diagnoses. These differences create uneven access to diagnosis, nutrition services, and treatment. Europe also has strong clinical nutrition demand because established hospitals and specialty providers use standardized parenteral and enteral products. Country-specific screening and reimbursement policies will continue to influence commercial access.

Asia-Pacific is projected to grow at an 8.80% CAGR through 2031, the highest regional rate in the malabsorption syndrome market. Asian inflammatory bowel disease prevalence rose materially and India had become the leading country for new incidence by 2025. East Asia recorded an annual age-standardized prevalence increase of 1.50%. Growing wheat-based diets may raise celiac disease risk in populations with limited diagnostic systems. The Middle East and Africa and South America remain earlier-stage regions, where limited treatment infrastructure restricts uptake. Brazil remains an anchor for South America, where clinical interest in pancreatic enzyme replacement for short bowel syndrome has increased.